PFO Closure: A Long Way to Success
- PMID: 40562468
- DOI: 10.1016/j.jcin.2025.05.027
PFO Closure: A Long Way to Success
Keywords: PASCAL classification; RoPE score; atrial fibrillation; cryptogenic stroke; residual shunt.
Conflict of interest statement
Funding Support and Author Disclosures Dr Sievert has received study honoraria to institution, travel expenses, and consulting fees from 4tech Cardio, Abbott, Ablative Solutions, Adona Medical, Akura Medical, Ancora Heart, Append Medical, Axon, Bavaria Medizin Technologie GmbH, Bioventrix, Boston Scientific, Cardiac Dimensions, Cardiac Success, Cardimed, Cardionovum, Celonova, Contego, Coramaze, Croivalve, CSL Behring LLC, CVRx, Dinova, Edwards Lifesciences, Endobar, Endologix, Endomatic, Esperion Therapeutics, Inc, Hangzhou Nuomao Medtech, Holistick Medical, Intershunt, Intervene, K2, Laminar, LifeTech, Magenta, Maquet Getinge Group, Metavention, Mitralix, Mokita, Neurotronic, NXT Biomedical, Occlutech, Recor, Renal Guard, Shifamed, Terumo, Trisol, Vascular Dynamics, Vectorious Medtech, Venus, Venock, Vivasure Medical, Vvital Biomed, and Whiteswell. Dr Piayda has received lecture honoraria and travel expenses from Edwards Lifesciences and Abbott. Dr Bertog has reported that he has no relationships relevant to the contents of this paper to disclose. There is surely room for improvement in device design and concepts here.
Publication types
LinkOut - more resources
Full Text Sources